Skip to main content
. 2015 Mar 13;4(7):1060–1068. doi: 10.1002/cam4.449

Figure 3.

Figure 3

Immunogenicity of interleukin-13-Pseudomonas exotoxin (IL-13-PE). The presence of neutralizing antibodies against IL-13-PE was monitored over time. (A) Neutralizing antibody titer detected in each patient during treatment. (B) Numbers of patients tested (Open bar) and positive (black bar) for neutralizing antibodies against PE or IL-13-PE at each treatment cycle.